Kura Oncology (NASDAQ:KURA – Get Rating) announced its earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.03, MarketWatch Earnings reports. During the same quarter last year, the company posted ($0.46) EPS.
Shares of KURA opened at $13.10 on Friday. The firm has a 50 day simple moving average of $15.80 and a 200-day simple moving average of $15.08. Kura Oncology has a 1-year low of $11.49 and a 1-year high of $26.41. The stock has a market cap of $872.98 million, a price-to-earnings ratio of -6.58 and a beta of 1.39.
Several brokerages have recently weighed in on KURA. Zacks Investment Research downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday. Jefferies Financial Group began coverage on shares of Kura Oncology in a research note on Tuesday, February 15th. They set a “buy” rating and a $35.00 target price for the company. StockNews.com began coverage on shares of Kura Oncology in a research note on Thursday, March 31st. They set a “sell” rating for the company. Credit Suisse Group increased their target price on shares of Kura Oncology from $25.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. Finally, SVB Leerink cut their price target on shares of Kura Oncology from $41.00 to $28.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $38.00.
Kura Oncology Company Profile (Get Rating)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.